Vanguard Short Term Corporate Bond ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Short Term Corporate Bond ETF trades at $78.52, while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| VCSH | ZBH | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $80.20 | $107.71 |
52-Week Low | $78.41 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
VCSH trades at $78.58, up 0.11% today, with a bearish technical signal from moving averages but neutral oscillators. The ETF maintains a 4.8% yield with recent dividends of $0.29-$0.30, though credit spreads are tight. News highlights institutional activity, including Apella Capital reducing its stake by 5.6% in Q2 2026 (SEC filing, August 7, 2026).
Outlook is cautious due to unattractive entry points and limited upside from rate cuts, per Seeking Alpha (July 27, 2026). Risks include credit spread widening and competition from alternatives like BSV. The short 2.7-year duration offers some downside protection, but yield advantages may narrow.
Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.
The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.
Trailing returns across standard periods
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →